Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Gemini Space Station Inc (GEMI) vs Repligen Corporation Common Stock (RGEN) Price & Performance

Gemini Space Station IncTrade
Repligen Corporation Common StockTrade

Price performance (Past 24H)

Key statistics

Gemini Space Station Inc vs Repligen Corporation Common Stock — how do they compare? Gemini Space Station Inc trades at $3.82 (market cap $531.57M), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: Repligen Corporation Common Stock is far larger — about 21× Gemini Space Station Inc's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, Gemini Space Station Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Gemini Space Station Inc for 15 Days and Repligen Corporation Common Stock for 0 Days on average.

GEMIRGEN
Market Cap
$531.57M$11.14B
Volume
1,676,3801,259,263
Sector
FinancialsHealth
52-Week High
$22.36$194.57
52-Week Low
$3.54$102.87
Typical Hold Time
15 Days0 Days
Enterprise Value
$510.60M$11.02B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Gemini Space Station Inc

Gemini Space Station (GEMI) trades at $4.10, down 0.24% with bearish technical signals despite recent price surges. The company reported Q2 2026 revenue growth of 37% year-over-year but missed earnings estimates with a net loss of -$517 million. Analyst consensus shows mixed sentiment with a $5.25 price target, while technical indicators show oversold conditions with RSI at 10.68.

The stock faces significant fundamental challenges with negative profit margins and cash burn, though revenue diversification shows promise. Near-term catalysts include SEC regulatory developments for tokenized stocks, but legal risks and persistent losses create substantial downside potential for investors.

Repligen Corporation Common Stock

RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.

Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

GEMI

No sentiment data available yet.

RGEN
100% Buy0% Sell
Avg holding period · 0 Days

Top news

Latest headlines on both assets

About Gemini Space Station Inc

Gemini Space Station Inc is the parent company of the Gemini crypto ecosystem, founded by Cameron and Tyler Winklevoss. It operates as a regulated digital asset exchange and custodian, providing a platform for individuals and institutions to trade, store, and stake cryptocurrencies while serving as a trusted bridge between legacy finance and the decentralized web.

Read more on GEMI →

About Repligen Corporation Common Stock

Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.

Read more on RGEN →